Theravance, Inc. (NASDAQ: THRX) announced the initiation of the dose-ranging Phase 2b Study 0117 with TD-4208 as a nebulized aqueous ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE